Table 3 ERβ1 expression levels in a population of breast cancer patients diagnosed at Mayo Clinic Rochester (cohort 1) and its association with other biomarkers, tumor grade and nodal status
Disease characteristics | ERβ1 status | Nucleus | Cytoplasm | |
|---|---|---|---|---|
# of Pts. (%) | # of Pts. (%) | |||
ERα | Positive (n = 170) | Negative/Low | 114 (67.1) | 151 (88.8) |
Moderate | 52 (30.6) | 19 (11.2) | ||
High | 4 (2.4) | 0 (0) | ||
Negative (n = 14) | Negative/Low | 7 (50.0) | 13 (92.9) | |
Moderate | 7 (50.0) | 1 (7.1) | ||
High | 0 (0) | 0 (0) | ||
HER2 | Positive (n = 27) | Negative/Low | 20 (74.1) | 24 (88.9) |
Moderate | 7 (25.9) | 3 (11.1) | ||
High | 0 (0) | 0 (0) | ||
Negative (n = 145) | Negative/Low | 94 (64.8) | 131 (90.4) | |
Moderate | 47 (32.4) | 14 (9.7) | ||
High | 4 (2.8) | 0 | ||
Ki67 | ≤ 10% (61) | Negative/Low | 39 (63.9) | 57 (93.4) |
Moderate | 21 (34.4) | 4 (6.6) | ||
High | 1 (1.6) | 0 (0) | ||
> 10% (120) | Negative/Low | 79 (65.8) | 104 (86.7) | |
Moderate | 38 (31.7) | 16 (13.3) | ||
High | 3 (2.5) | 0 (0) | ||
Tumor grade | Grade 1–2 (136) | Negative/Low | 89 (65.4) | 122 (89.7) |
Moderate | 44 (32.4) | 14 (10.3) | ||
High | 3 (2.2) | 0 | ||
Grade 3 (45) | Negative/Low | 31 (68.9) | 41 (91.1) | |
Moderate | 13 (28.9) | 4 (8.9) | ||
High | 1 (2.2) | 0 (0) | ||
Nodal disease | Present (72) | Negative/Low | 44 (61.1) | 65 (90.3) |
Moderate | 24 (33.3) | 7 (9.7) | ||
High | 4 (5.6) | 0 (0) | ||
Not present (112) | Negative/Low | 77 (68.8) | 99 (88.4) | |
Moderate | 35 (31.3) | 13 (11.6) | ||
High | 0 (0) | 0 (0) |